ANCA–Associated Small-Vessel Vasculitis

ISHAK A. MANSI, M.D., PH.D., ADRIANA OPRAN, M.D., and FRED ROSNER, M.D.
Mount Sinai Services at Queens Hospital Center, Jamaica, New York
and the Mount Sinai School of Medicine, New York, New York

Antineutrophil cytoplasmic antibodies (ANCA)–associated vasculitis is the most common primary systemic small-vessel vasculitis to occur in adults. Although the etiology is not always known, the incidence of vasculitis is increasing, and the diagnosis and management of patients may be challenging because of its relative infrequency, changing nomenclature, and variability of clinical expression. Advances in clinical management have been achieved during the past few years, and many ongoing studies are pending. Vasculitis may affect the large, medium, or small blood vessels. Small-vessel vasculitis may be further classified as ANCA-associated or non-ANCA–associated vasculitis. ANCA–associated small-vessel vasculitis includes microscopic polyangiitis, Wegener's granulomatosis, Churg-Strauss syndrome, and drug-induced vasculitis. Better definition criteria and advancement in the technologies make these diagnoses increasingly common. Features that may aid in defining the specific type of vasculitic disorder include the type of organ involvement, presence and type of ANCA (myeloperoxidase–ANCA or proteinase 3–ANCA), presence of serum cryoglobulins, and the presence of evidence for granulomatous inflammation. Family physicians should be familiar with this group of vasculitic disorders to reach a prompt diagnosis and initiate treatment to prevent end-organ damage. Treatment usually includes corticosteroid and immunosuppressive therapy. (Am Fam Physician 2002;65:1615-20. Copyright © 2002 American Academy of Family Physicians.)

Vasculitis is a process caused by inflammation of blood vessel walls and results in a variety of disorders. A good and accepted classification system for vasculitis has not emerged, although it may be categorized by the size or type of the involved blood vessel as large-, medium-, or small-vessel vasculitis. Small-vessel vasculitis is defined as vasculitis that affects vessels smaller than arteries (i.e., arterioles, venules, and capillaries); however, small-vessel vasculitis can also involve medium-sized arteries. Figure 1 illustrates some major classifications of vasculitis and illustrates the position of antineutrophil cytoplasmic antibodies (ANCA)–associated vasculitis among other types. It is the most common cause of small-vessel vasculitis and includes microscopic polyangiitis, Wegener's granulomatosis, Churg-Strauss syndrome, and certain types of drug-induced vasculitis.

What are ANCA?

ANCA are specific antibodies for antigens in cytoplasmic granules of neutrophils and monocyte lysosomes, first reported in 1982. These antibodies can be detected with indirect immunofluorescence microscopy. Two major patterns of staining are present: cytoplasmic ANCA (c–ANCA) and peri-nuclear ANCA (p–ANCA). Specific immunochromatic assays demonstrate that c–ANCA is mainly antibodies to proteinase 3, and p–ANCA is antibodies to myeloperoxidase. Using antigen-specific immunochemical assay to characterize ANCA (rather than the pattern of immunofluorescence microscopy) is more specific and more clinically relevant; therefore, the terms proteinase 3–ANCA (PR3–ANCA) and myeloperoxidase–ANCA (MPO–ANCA) are now in use.
Diagnosis of Small-Vessel Vasculitis

Small-vessel vasculitis has common features that should alert the family physician to consider its presence. Three questions should be asked in this regard and are addressed in this article: (1) “Is small-vessel vasculitis present?”; (2) “Which specific type of small-vessel vasculitis is present?” and (3) “Is the diagnosis of the specific type of small-vessel vasculitis important?”

**IS SMALL-VESEL VASCULITIS PRESENT?**

Table 1 summarizes the potential clinical manifestations of ANCA–associated small-vessel vasculitis that is generally shared by most types of small-vessel vasculitis. Small-vessel vasculitis should be suspected in any patient who presents with a multisystem disease that is not caused by an infectious or malignant process (e.g., renal dysfunction, skin rashes, pulmonary manifestations, or neurologic manifestation).<sup>5-8</sup> Constitutional symptoms are common. The frequency and combination of various system involvements vary among individual disease entities.

The most common cutaneous lesion is palpable purpura—a slightly raised, non-

---

### Clinical Manifestations of ANCA–Associated Small-Vessel Vasculitis

- **Vasculitis**
  - Medium-size vessel vasculitis
    - Polyarteritis nodosa
    - Kawasaki’s disease
  - Small-vessel vasculitis
    - ANCA–associated small-vessel vasculitis
      - Wegener’s granulomatosis
      - Microscopic polyangiitis
      - Churg-Strauss syndrome
      - Drug induced
    - Non-ANCA small-vessel vasculitis
      - Paraneoplastic small-vessel vasculitis
      - Immune-complex small-vessel vasculitis
        - Henoch-Schönlein purpura
        - Cryoglobulinemic vasculitis
        - Lupus vasculitis
        - Rheumatoid arthritis
        - Goodpasture’s syndrome
        - Sjögren’s disease
        - Drug-induced immune-complex vasculitis
        - Behçet’s disease
        - Infection-induced immune-complex vasculitis
    - Inflammatory bowel disease vasculitis
  - Large-vessel vasculitis
    - Giant cell arteritis
    - Takayasu’s disease

---

**TABLE 1**

**Clinical Manifestations of ANCA–Associated Small-Vessel Vasculitis**

<table>
<thead>
<tr>
<th>System</th>
<th>Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constitutional</td>
<td>Fever, weight loss, anorexia, general malaise</td>
</tr>
<tr>
<td>Musculoskeletal skin</td>
<td>Myalgia, arthralgia</td>
</tr>
<tr>
<td>Kidneys</td>
<td>Palpable purpura, urticaria</td>
</tr>
<tr>
<td>Kidneys</td>
<td>Proteinuria, hematuria, renal insufficiency, renal failure, necrotizing glomerulonephritis</td>
</tr>
<tr>
<td>Respiratory tract</td>
<td>Dyspnea, cough, hemoptysis; lung infiltrate, interstitial lung disease, pulmonary hemorrhage</td>
</tr>
<tr>
<td>Nervous system</td>
<td>Peripheral neuropathy, especially mononeuritis</td>
</tr>
<tr>
<td>Gastrointestinal tract</td>
<td>Fecal blood, elevated liver enzymes; diarrhea, nausea, vomiting, abdominal pain</td>
</tr>
</tbody>
</table>

*Information from references 5-8.*
blanching eruption that usually begins in the lower extremities. Occasionally, the rash is vesicular or slightly ulcerated. Urticaria can also be a manifestation of small-vessel vasculitis. Unlike nonvasculitic allergic urticaria, vasculitic urticaria lasts more than one day and may evolve into purpuric lesions. The presence of hypocomplementemia may indicate that the vasculitis is immune complex-mediated rather than ANCA–associated primary vasculitis.

Renal involvement in vasculitis may progress to renal failure. Results of biopsy of the kidney commonly reveals glomerulonephritis. Focal necrosis, crescentic formation and the absence or paucity of immunoglobulin deposits char-

---

**Figure 2.** Differential diagnosis of ANCA– and non-ANCA–associated small-vessel vasculitis. (ANCA = anti-neutrophilic cytoplasmic antibodies; Ig-A = immunoglobulin A)

*—In ANCA–associated vasculitis, the absence of granulomas differentiates microscopic polyangiitis from other types. Whereas in the presence of granuloma, the symptoms, the organ involved, and type of ANCA differentiate Wegener’s granulomatosis from Churg-Strauss syndrome.

†—Testing for ANCA, vascular immunoglobulin A deposits, and serum cryoglobulins facilitates the diagnostic characterization of small vessel vasculitis.

ANCA–associated small-vessel vasculitis is the most common primary type in adults; whereas, Henoch-Schönlein purpura is most common in children.

...characterize glomerulonephritis in patients with ANCA–associated vasculitis.6

Lung involvement ranges from fleeting focal infiltrates or interstitial disease to massive pulmonary hemorrhagic alveolar capillaritis. The latter is the most life-threatening feature of small-vessel vasculitis.4,5,7,8

It is important, however, to differentiate small-vessel vasculitis from other diseases that result in multisystem manifestations. Diseases with widespread embolization to different organs (e.g., atheroembolic disease, endocarditis, antiphospholipid syndrome, and atrial myxoma) can produce similar clinical presentations.9 Persons with sepsis can also present with multisystem involvement. It is also important to realize that small-vessel vasculitis may be secondary to infections or malignancy. Some viral, bacterial, and fungal infections may be complicated by vasculitis, which is predominantly a dermal vasculitis.9 The diagnosis is suggested by the clinical history. Malignancy, such as lymphomas, leukemia, myeloproliferative, and myelodysplastic syndromes may be associated with vasculitis; however, solid tumors are less commonly associated with vasculitis.9 It must be emphasized that underlying infectious or malignant causes should be thoroughly evaluated before the diagnosis of primary vasculitis is made—even if the ANCA assay result is positive.

WHAT SPECIFIC TYPE OF SMALL-VESEL VASCULITIS IS IT?

Table 2 depicts some of the clinical features that may help in the diagnosis of the specific type of vasculitis. Laboratory assessment should include a complete blood cell count and routine chemistry profile, urinalysis, fecal occult blood test, and chest radiography.9 There may be normocytic anemia, thrombocytosis, elevated erythrocyte sedimentation rate, increased liver function, or evidence of renal involvement. ANCA serum levels should also be measured. Other laboratory tests that should be performed to exclude ANCA–associated small-vessel vasculitis include antinuclear antibody, rheumatoid factor, cryoglobulins, complement, antibodies to hepatitis B and C, and human immunodeficiency virus (HIV) testing.9 Chest and sinus computed tomographic scans may also be performed, if appropriate. Angiography may reveal evidence of medium- or large-vessel vasculitis. Pathologic examination of the involved tissue (e.g., skin, nerve, lung, or kidney) may aid in documenting the type of small-vessel vasculitis. Biopsy should be obtained from symptomatic and accessible sites. Biopsies from asymptomatic sites have a low yield of positive results.1,8,9

ANCA-associated small-vessel vasculitis is the most common primary type of vasculitis in older adults, while Henoch-Schönlein purpura is most common in children.9

Wegener’s Granulomatosis. Wegener’s granulomatosis commonly has the classic triad of involvement of the upper respiratory tract,
Upper respiratory tract signs and symptoms include sinusitis, nasal ulcers, otitis media, or hearing loss. Upper respiratory tract signs and symptoms are seen in 70 percent of patients and pulmonary infiltrates or nodules that may cavitate develop in 85 percent of patients. Serum antiprotease 3-ANCA (c-ANCA) is positive in 75 to 90 percent, although 20 percent may have positive p-ANCA. Open lung biopsy is the most definitive diagnostic test. Sinus biopsy is diagnostic in only 30 percent of cases because inflammatory findings are often nonspecific and renal biopsy is also relatively nonspecific.

Wegener’s granulomatosis can affect patients at any age, with the peak incidence during the fourth decade of life and is slightly more common in men.

Microscopic Polyangiitis. Microscopic polyangiitis is the most common ANCA-associated small-vessel vasculitis, and is characterized by the presence of ANCA and few or no immune deposits in the involved vessels. The kidneys are the most commonly affected organs in 90 percent of patients who have this type of vasculitis. Patients present with variable combinations of renal manifestations, palpable purpura, abdominal pain, cough, and hemoptysis. Most patients have positive MPO-ANCA (p-ANCA), although PR3-ANCA (c-ANCA) may be also present in 40 percent of patients. The most common age of onset is 40 to 60 years and is more common in men.

Churg-Strauss Syndrome. Churg-Strauss syndrome is a rare disease and has three phases: allergic rhinitis and asthma, eosinophilic infiltrative disease resembling pneumonia, and systemic small vessel vasculitis with granulomatous inflammation. The vasculitic phase usually develops within three years of the onset of asthma. Almost all patients have more than 10 percent eosinophils in the blood. Coronary arteritis and myocarditis are the principal causes of morbidity and mortality. The age of onset varies from 15 to 70 years and is more common in men.

Drug-Induced Vasculitis. Drug-induced vasculitis usually develops within seven to 21 days after a drug is started and may be confined to the skin. Skin lesions are identical to those seen in systemic small vessel vasculitis. Drugs cause approximately 10 percent of vasculitic skin lesions. Drugs that have been implicated include penicillin, aminopenicillins, sulfonamides, allopurinol, thiazides, quinolones, hydantoins, and propylthiouracil. Some drugs, such as propylthiouracil and hydralazine (Apresoline), appear to cause vasculitis by inducing ANCA.

IS THE DIAGNOSIS OF THE SPECIFIC TYPE OF SMALL-VEssel VASCULITIS IMPORTANT?
A rapid diagnosis of ANCA-associated small-vessel vasculitis is critically important, because life-threatening injury to organs often develops quickly and is mitigated dramatically by immunosuppressive therapy. On the other hand, because the treatment of patients with microscopic polyangiitis or Wegener’s granulomatosis is essentially the same when there is major organ injury, it is unnecessary to distinguish conclusively between these closely related variants of ANCA-associated small-vessel vasculitis before initiating treatment.

Treatment
Treatment of patients with microscopic polyangiitis and Wegener’s granulomatosis has three phases: (1) induction of remission, (2) maintenance of remission, and (3) treatment of relapse. Current induction therapy often consists of cyclophosphamide (Cytoxan) and corticosteroids. For aggressive disease, use of high-dose intravenous methylprednisolone for three days is recommended, combined with intravenous or oral cyclophosphamide. Tapering doses of prednisone should follow, along with cyclophosphamide maintenance for 12 to 18 months. The lowest dosage of steroids that controls the disease should be used, and infection should be considered if the symptoms appear to exacerbate. For patients in sustained remission at 12 months, the use of...
all medications may be gradually discontinued. Patients whose symptoms are under good control must, nevertheless, be closely followed at six-month intervals for signs and symptoms of relapse. During treatment with these agents, complete blood counts and liver function tests should be performed periodically.11

Other treatment regimens that may be of benefit include methotrexate, azathioprine (Imuran), trimethoprim-sulfamethoxazole (Bactrim, Septra), plasma exchange, cyclosporine (Sandimmune), intravenous immunoglobulin, and monoclonal antibodies.11 During the use of potentially ulcerogenic immunosuppressive therapy, patients may be given H2-blockers or proton-pump inhibitors. Prophylactic treatment with fluconazole (Diflucan) orally for fungal infection may be considered, as well as trimethoprim-sulfamethoxazole (480 mg) three times weekly for prophylactic treatment of patients with pneumocystis carinii prophylaxis.11 Patients with Churg-Strauss syndrome usually respond to high-dose corticosteroid therapy alone, although some cases may require the addition of cytotoxic drugs.11 Comorbid conditions that accelerate vascular damage, such as hypertension, diabetes, hypercholesterolemia, and smoking should be appropriately controlled.

In drug-induced vasculitis, the offending agent should be stopped. Antihistamines and nonsteroidal anti-inflammatory drugs help alleviate skin discomfort and reduce associated arthralgias and myalgias. Severe cutaneous disease may warrant oral corticosteroid therapy.1

The authors indicate that they do not have any conflicts of interest. Sources of funding: none reported.

REFERENCES


The Authors

ISHAK A. MANSI, M.D., PH.D., is in private practice at Garden Medical Clinic, Garden City, Kan. Dr. Mansi received his medical degree from Mansourah Faculty of Medicine, Mansourah, Egypt, and completed his initial post-graduate training at Ain-Shams University, Cairo, Egypt, where he received a doctorate degree in cardiology. Dr. Mansi completed a residency in internal medicine at the Catholic Medical Center, Jamaica, N.Y. Dr. Mansi received his medical degree from Mansourah Faculty of Medicine, Mansourah, Egypt, and completed his initial post-graduate training at Ain-Shams University, Cairo, Egypt, where he received a doctorate degree in cardiology. Dr. Mansi completed a residency in internal medicine at the Catholic Medical Center, Jamaica, N.Y. and a fellowship in rheumatology at Ain-Shams University, Cairo, Egypt, and completed his initial post-graduate training at Ain-Shams University, Cairo, Egypt, where he received a doctorate degree in cardiology. Dr. Mansi completed a residency in internal medicine at the Catholic Medical Center, Jamaica, N.Y. and a fellowship in internal medicine at Mount Sinai School of Medicine, Queens Hospital Center Affiliation, Jamaica, N.Y.

ADRIANA OPRAN, M.D., is the chief of the Division of Rheumatology and assistant professor of medicine, Mount Sinai School of Medicine, Queens Hospital Center. Dr. Opran received her medical degree from Timisoara Medical School, Romania. She completed a residency in internal medicine at the Catholic Medical Center, Jamaica, N.Y. and a fellowship in rheumatology, Long Island Jewish Medical Center, N.Y.

FRED ROSNER, M.D., is director of the Department of Medicine, Mount Sinai Services, Queens Hospital Center, and professor of medicine, Mount Sinai School of Medicine, New York City. He earned his medical degree from Yeshiva University’s Albert Einstein College of Medicine, Bronx, N.Y. Dr. Rosner completed a residency in internal medicine and fellowship hematology, Maimonides Medical Center, Brooklyn, N.Y.

Address correspondence to Adriana Opran, M.D., Department of Medicine, Mount Sinai Services at Queens Hospital Center, 82-68 164th Street, Jamaica, NY 11432.